Skip to main content
Clinical Trials/NCT01892813
NCT01892813
Unknown
Phase 3

Tailored Tobacco Intervention

Mark Vander Weg1 site in 1 country411 target enrollmentJuly 2013

Overview

Phase
Phase 3
Intervention
Nicotine replacement therapy - Transdermal nicotine patch
Conditions
Nicotine Dependence
Sponsor
Mark Vander Weg
Enrollment
411
Locations
1
Primary Endpoint
Tobacco use
Last Updated
8 years ago

Overview

Brief Summary

The project is designed to examine the effectiveness of strategies to increase access to treatment for tobacco use and dependence among rural Veteran smokers. In addition, it will examine whether tailored treatment that is designed to address common comorbid conditions that are related to cigarette smoking enhances success with quitting relative to enhanced standard of care. The investigators hypothesize that participants assigned to the tailored tobacco cessation intervention will report greater cessation rates at six months. The investigators also anticipate more favorable outcomes on measures of depressive symptoms, alcohol use, and body weight.

Registry
clinicaltrials.gov
Start Date
July 2013
End Date
January 2018
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Mark Vander Weg
Responsible Party
Sponsor Investigator
Principal Investigator

Mark Vander Weg

Associate Professor of Internal Medicine

University of Iowa

Eligibility Criteria

Inclusion Criteria

  • Veteran status
  • 18 + years of age
  • Smoke cigarettes on at least a daily basis
  • Receive primary care from the Iowa City VA Health Care System or an affiliated Community-based Outpatient Clinic (CBOC)
  • Live in a non-metropolitan area (based on Rural-Urban Commuting Area Codes (RUCA) codes)
  • Be willing to make an attempt to quit smoking in the next 30 days
  • Be capable of providing informed consent
  • Have access to a telephone (land line or cell phone)
  • Have a stable residence

Exclusion Criteria

  • Planning to move within the next 12 months
  • Presence of a terminal illness
  • Pregnancy
  • Unstable psychiatric disorder (e.g., acute psychosis)
  • Currently pregnant
  • Incarcerated
  • Institutionalized

Arms & Interventions

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Nicotine replacement therapy - Transdermal nicotine patch

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Nicotine replacement therapy - Nicotine gum

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Nicotine replacement therapy - Nicotine lozenge

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Bupropion

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Varenicline

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Combination pharmacotherapy - Transdermal nicotine patch + bupropion

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Tailored behavioral intervention

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Alcohol use risk reduction

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Behavioral activation for depressive symptoms

Tailored intervention

Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.

Intervention: Behavioral management of postcessation weight gain

Enhanced standard of care

Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.

Intervention: Nicotine replacement therapy - Transdermal nicotine patch

Enhanced standard of care

Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.

Intervention: Nicotine replacement therapy - Nicotine gum

Enhanced standard of care

Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.

Intervention: Nicotine replacement therapy - Nicotine lozenge

Enhanced standard of care

Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.

Intervention: Bupropion

Enhanced standard of care

Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.

Intervention: Varenicline

Enhanced standard of care

Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.

Intervention: Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum

Enhanced standard of care

Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.

Intervention: Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge

Enhanced standard of care

Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.

Intervention: Combination pharmacotherapy - Transdermal nicotine patch + bupropion

Enhanced standard of care

Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.

Intervention: Tobacco quitline referral

Outcomes

Primary Outcomes

Tobacco use

Time Frame: Six-month follow-up

At the six-month follow-up contact, participants will be questioned regarding self-reported tobacco use over the past seven and 30 days.

Secondary Outcomes

  • Alcohol use(Six-month follow-up)
  • Depressive symptoms(Six-month follow-up)
  • Body weight(Six-month follow-up)
  • Physical Activity(Six-month follow-up)
  • Dietary intake(Six-month follow-up)

Study Sites (1)

Loading locations...

Similar Trials